Keytruda (pembrolizumab)

pCPA File Number: 23010

Negotiation Status:

Concluded with an LOI

Indication(s):

as monotherapy for the adjuvant treatment of adult patients with Stage IB (T2a 4 cm), II, or IIIA NSCLC, and with PD-L1 tumor proportion score (TPS) less than 50% who have undergone complete resection and platinum-based chemotherapy.

Sponsor/Manufacturer:

Merck Canada Inc.

CDA-AMC Project Number:

PC0369-000

pCPA Engagement Letter Issued:

2025-02-20

Negotiation Process Concluded:

2025-02-20